# First-line Treatment with Furmonertinib Mesylate in Lung Adenocarcinoma Patient with EGFR Exon 20 Insertion Mutantion

## TL;DR

This paper reports on a lung adenocarcinoma patient with an EGFR exon 20 insertion mutation treated with furmonertinib mesylate.

## Contribution

The study provides a clinical case summary of furmonertinib mesylate as a potential first-line treatment for EGFR exon 20 insertion mutations.

## Key findings

- Furmonertinib mesylate was used to treat a patient with EGFR exon 20 insertion mutation lung adenocarcinoma.
- The treatment outcome is shared to inform clinical practice for similar cases.
- The case highlights the evolving treatment landscape for NSCLC with molecularly targeted therapies.

## Abstract

随着基因组学、蛋白组学和分子生物检测技术的不断创新，晚期非小细胞肺癌（non-small cell lung cancer, NSCLC）的治疗模式逐渐多样化，已经从传统的化疗逐渐过渡到免疫治疗及靶向治疗。其中，以靶向酪氨酸激酶通路为靶点的分子肿瘤标志物在临床中发挥着越来越重要的作用。针对NSCLC患者表皮生长因子受体（epidermal growth factor receptor, EGFR）突变阳性，现阶段市面上已经有众多一线治疗药物上市，且均有较为明显的治疗效果。在中国患者中EGFR常见的变异位点位于19、20和21号外显子上，其中19和21号外显子突变是较为常见的突变类型，除此以外，EGFR突变还有一种亚型，被称为EGFR 20号外显子插入（EGFR exon 20 insertion, EGFR 20ins）突变。我们针对1例EGFR 20ins突变肺腺癌患者接受甲磺酸伏美替尼治疗进行总结，以期为临床诊疗提供有效借鉴。